Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Seiwerth

Showing results (141-150 of 179) with videos related to

Pageof 18
Sort By:
Journal of Pharmacological Sciences|September 27, 2008
Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-systemRobert Klicek, Marko Sever, Bozo Radic, et al.
World Journal of Gastroenterology|August 7, 2023
Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effectLuka Kalogjera, Ivan Krezic, Ivan Maria Smoday, et al.
Vascular Pharmacology|March 7, 2018
Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157Jakša Vukojević, Marko Siroglavić, Katarina Kašnik, et al.
Pharmaceuticals (Basel, Switzerland)|June 28, 2023
Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as TherapySanja Strbe, Ivan Maria Smoday, Ivan Krezic, et al.
Pharmaceuticals (Basel, Switzerland)|February 27, 2026
Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A ReviewDanijel Matek, Irena Matek, Mladen Japjec, et al.
Life Sciences|February 8, 2011
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesionsSpomenko Ilic, Domagoj Drmic, Sandra Franjic, et al.
Pharmaceuticals (Basel, Switzerland)|April 27, 2024
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter ActivityPredrag Sikiric, Alenka Boban Blagaic, Sanja Strbe, et al.
Journal of Pharmacological Sciences|April 25, 2007
Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157Ivan Dobric, Petar Drvis, Igor Petrovic, et al.
World Journal of Gastroenterology|January 24, 2018
Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insightsAntonija Duzel, Josipa Vlainic, Marko Antunovic, et al.
Current Pharmaceutical Design|July 13, 2018
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone HealingSven Seiwerth, Rudolf Rucman, Branko Turkovic, et al.
Pageof 18

Showing results (141-150 of 179) with videos related to

Sort By:
Pageof 18
Journal of Pharmacological Sciences|September 27, 2008
Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-systemRobert Klicek, Marko Sever, Bozo Radic, et al.
World Journal of Gastroenterology|August 7, 2023
Stomach perforation-induced general occlusion/occlusion-like syndrome and stable gastric pentadecapeptide BPC 157 therapy effectLuka Kalogjera, Ivan Krezic, Ivan Maria Smoday, et al.
Vascular Pharmacology|March 7, 2018
Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157Jakša Vukojević, Marko Siroglavić, Katarina Kašnik, et al.
Pharmaceuticals (Basel, Switzerland)|June 28, 2023
Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as TherapySanja Strbe, Ivan Maria Smoday, Ivan Krezic, et al.
Pharmaceuticals (Basel, Switzerland)|February 27, 2026
Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157-A ReviewDanijel Matek, Irena Matek, Mladen Japjec, et al.
Life Sciences|February 8, 2011
Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesionsSpomenko Ilic, Domagoj Drmic, Sandra Franjic, et al.
Pharmaceuticals (Basel, Switzerland)|April 27, 2024
The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter ActivityPredrag Sikiric, Alenka Boban Blagaic, Sanja Strbe, et al.
Journal of Pharmacological Sciences|April 25, 2007
Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157Ivan Dobric, Petar Drvis, Igor Petrovic, et al.
World Journal of Gastroenterology|January 24, 2018
Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insightsAntonija Duzel, Josipa Vlainic, Marko Antunovic, et al.
Current Pharmaceutical Design|July 13, 2018
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone HealingSven Seiwerth, Rudolf Rucman, Branko Turkovic, et al.
Pageof 18